Candid Therapeutics, Inc.
Candid Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is dedicated to advancing innovative therapies for patients with unmet medical needs. Founded in 2018, Candid Therapeutics focuses on developing cutting-edge treatments in the fields of neurology and rare diseases, leveraging its expertise in drug discovery and development. The company’s core offerings include a unique portfolio of therapeutic candidates designed to address complex neurological disorders. Candid Therapeutics distinguishes itself through its commitment to precision medicine and patient-centric approaches, aiming to improve outcomes for individuals suffering from debilitating conditions. With a strong market position and a growing reputation for excellence, Candid Therapeutics continues to make significant strides in the biopharmaceutical industry, contributing to the advancement of healthcare solutions.
DitchCarbon Score
How does Candid Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Candid Therapeutics, Inc.'s score of 33 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Candid Therapeutics, Inc.'s reported carbon emissions
In 2024, Candid Therapeutics, Inc. reported total carbon emissions of approximately 499,725,000 kg CO2e, comprising 430,362,000 kg CO2e from Scope 1 and 69,363,000 kg CO2e from Scope 2 emissions. This reflects a slight decrease from 2023, where total emissions were about 534,773,000 kg CO2e, with Scope 1 emissions at 459,896,000 kg CO2e and Scope 2 emissions at 74,877,000 kg CO2e. Candid Therapeutics has set ambitious reduction targets, aiming to reduce absolute Scope 1 and Scope 2 emissions by more than 40% by 2025 from a 2007 baseline. Additionally, the company plans to achieve a 50% reduction in these emissions by 2035, using a 2020 baseline. These commitments demonstrate a proactive approach to mitigating climate impact and align with industry standards for sustainability. The company does not currently report Scope 3 emissions, which encompass indirect emissions from the value chain. Candid Therapeutics' emissions data is not cascaded from any parent organisation, indicating that the reported figures are solely from its own operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 4,775,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,458,000 | 0,000,000 | 000,000 | 0,000,000 |
| Scope 3 | 7,168,000 | 0,000,000 | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Candid Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
